Oncomine has 380 citations.

2010  |  2009  |  2008  |  2007  |  2006–2004  |   Download a list of references.

1. Identification of DOK genes as lung tumor suppressors.
   Berger AH, Niki M, Morotti A, Taylor BS, Socci ND, Viale A, Brennan C, Szoke J, Motoi N, Rothman PB, Teruya-Feldstein J, Gerald WL, Ladanyi M, Pandolfi PP.
   Nat Genet. 2010 Mar;42(3):216-23. Epub 2010 Feb 7. Pubmed
2. Cancer-Associated Fibroblasts Are Activated in Incipient Neoplasia to Orchestrate Tumor-Promoting Inflammation in an NF-kappaB-Dependent Manner.
   Erez N, Truitt M, Olson P, Hanahan D.
   Cancer Cell. 2010 Feb 17;17(2):135-47. Epub 2010 Feb 4. Pubmed
3. The potential value of microseminoprotein-beta as a prostate cancer biomarker and therapeutic target.
   Whitaker HC, Warren AY, Eeles R, Kote-Jarai Z, Neal DE.
   Prostate. 2010 Feb 15;70(3):333-40. Pubmed
4. Enhanced mRNA cap methylation increases cyclin D1 expression and promotes cell transformation.
   Cowling VH.
   Oncogene. 2010 Feb 11;29(6):930-6. Epub 2009 Nov 16. Pubmed
5. Sex determining region Y-Box 2 (SOX2) is a potential cell-lineage gene highly expressed in the pathogenesis of squamous cell carcinomas of the lung.
   Yuan P, Kadara H, Behrens C, Tang X, Woods D, Solis LM, Huang J, Spinola M, Dong W, Yin G, Fujimoto J, Kim E, Xie Y, Girard L, Moran C, Hong WK, Minna JD, Wistuba II.
   PLoS One. 2010 Feb 9;5(2):e9112. Pubmed
6. Mutant EGFR is required for maintenance of glioma growth in vivo, and its ablation leads to escape from receptor dependence.
   Mukasa A, Wykosky J, Ligon KL, Chin L, Cavenee WK, Furnari F.
   Proc Natl Acad Sci U S A. 2010 Feb 9;107(6):2616-21. Epub 2010 Jan 21. Pubmed
7. Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group.
   Hertzberg L, Vendramini E, Ganmore I, Cazzaniga G, Schmitz M, Chalker J, Shiloh R, Iacobucci I, Shochat C, Zeligson S, Cario G, Stanulla M, Strehl S, Russell LJ, Harrison CJ, Bornhauser B, Yoda A, Rechavi G, Bercovich D, Borkhardt A, Kempski H, te Kronnie G, Bourquin JP, Domany E, Izraeli S.
   Blood. 2010 Feb 4;115(5):1006-17. Epub 2009 Nov 24. Pubmed
8. Mitotic chromosomal instability and cancer: mouse modelling of the human disease.
   Schvartzman JM, Sotillo R, Benezra R.
   Nat Rev Cancer. 2010 Feb;10(2):102-15. Pubmed
9. Emerging roles of deubiquitinases in cancer-associated pathways.
   Sacco JJ, Coulson JM, Clague MJ, Urbé S.
   IUBMB Life. 2010 Feb;62(2):140-57. Pubmed
10. A multiple-filter-multiple-wrapper approach to gene selection and microarray data classification.
    Leung Y, Hung Y.
    IEEE/ACM Trans Comput Biol Bioinform. 2010 Jan-Mar;7(1):108-17. Pubmed
11. Regulation of the histone demethylase JMJD1A by hypoxia-inducible factor 1 alpha enhances hypoxic gene expression and tumor growth.
    Krieg AJ, Rankin EB, Chan D, Razorenova O, Fernandez S, Giaccia AJ.
    Mol Cell Biol. 2010 Jan;30(1):344-53. Pubmed
12. Regulation of alphaB-crystallin gene expression by the transcription factor Ets1 in breast cancer.
    Bosman JD, Yehiely F, Evans JR, Cryns VL.
    Breast Cancer Res Treat. 2010 Jan;119(1):63-70. Epub 2009 Feb 11. Pubmed
13. SOX2 is an oncogene activated by recurrent 3q26.3 amplifications in human lung squamous cell carcinomas.
    Hussenet T, Dali S, Exinger J, Monga B, Jost B, Dembelé D, Martinet N, Thibault C, Huelsken J, Brambilla E, du Manoir S.
    PLoS One. 2010 Jan 29;5(1):e8960. Pubmed
14. SIRT3 is a mitochondria-localized tumor suppressor required for maintenance of mitochondrial integrity and metabolism during stress.
    Kim HS, Patel K, Muldoon-Jacobs K, Bisht KS, Aykin-Burns N, Pennington JD, van der Meer R, Nguyen P, Savage J, Owens KM, Vassilopoulos A, Ozden O, Park SH, Singh KK, Abdulkadir SA, Spitz DR, Deng CX, Gius D.
    Cancer Cell. 2010 Jan 19;17(1):41-52. Pubmed
15. RalA suppresses early stages of Ras-induced squamous cell carcinoma progression.
    Sowalsky AG, Alt-Holland A, Shamis Y, Garlick JA, Feig LA.
    Oncogene. 2010 Jan 7;29(1):45-55. Epub 2009 Oct 5. Pubmed
16. Gene expression analysis of macrophages that facilitate tumor invasion supports a role for Wnt-signaling in mediating their activity in primary mammary tumors.
    Ojalvo LS, Whittaker CA, Condeelis JS, Pollard JW.
    J Immunol. 2010 Jan 15;184(2):702-12. Epub 2009 Dec 16. Pubmed
17. Global levels of histone modifications predict prostate cancer recurrence.
    Ellinger J, Kahl P, von der Gathen J, Rogenhofer S, Heukamp LC, Gütgemann I, Walter B, Hofstädter F, Büttner R, Müller SC, Bastian PJ, von Ruecker A.
    Prostate. 2010 Jan 1;70(1):61-9. Pubmed
18. Functional genomic analysis of glioblastoma multiforme through short interfering RNA screening: a paradigm for therapeutic development.
    Thaker NG, Zhang F, McDonald PR, Shun TY, Lazo JS, Pollack IF.
    Neurosurg Focus. 2010 Jan;28(1):E4. Pubmed
19. Putative molecular signatures for the imaging of prostate cancer.
    Yang S Y, Adelstein J, Kassis AI.
    Expert Rev Mol Diagn. 2010 Jan;10(1):65-74. Pubmed
20. Expression of the actin-associated protein transgelin (SM22) is decreased in prostate cancer.
    Prasad PD, Stanton JA, Assinder SJ.
    Cell Tissue Res [Epub ahead of print] Pubmed